Why The Mortality Risk For Transgender Men And Women Is Double Than Cisgenders?
According to a five-decade study of data. Transgender men and women are twice as likely to die as their cisgender counterparts. According to a five-decade study of data. There is no evidence to suggest that the mortality risk for transgender persons has decreased over time, according to one study. Rather, the danger was doubled.
Thus, transgender women had a greater mortality risk than transgender males. It was published in The Lancet Diabetes and Endocrinology.
Researchers studied 4568 transgender individuals between 1972 and 2018.
The Mortality Risk
2927 transgender women and 1641 male transgender had their medical records. Which was done at the Amsterdam UMC gender identity clinic between 1972 and 2018 analyzed. Hormone therapy was also being administered to them.
Treatment type, smoking habits, medical history, and final follow-up date were all recorded. Transgender males and transgender women were on average 30 years old and 23 years old.
Researchers compared the death rates of transgender men and women with the general Dutch population. Statistics Netherlands (CBS) data was used to do this study.
According to the study’s classification of deaths, cardiovascular disease, infection, cancer, and non-natural causes of death were all examined. During follow-up, 317 transgender women and 44 transgender males, or 10.8% and 2.7%, respectively, died. Deaths per 100,000 persons increased to 628 in a single year as a result of this.
Between 1972 and 2018, the mortality risk did not decrease. The mortality risk of transgender women in the Dutch population was twice that of cis males. Approximately three times that of cis women, according to a new study.1.4 is the mortality ratio of transgender women as compared to cis males.
The reason being cardiovascular illness. Transgender women have 1.4 times the chance of death as cis men have when it comes to cardiovascular disease. Lung cancer, infection, and other non-natural causes of death had mortality rates of 2, 5, and 2. When it comes to HIV-related diseases, transgender women’s mortality risk is 15 times higher than that of cis men.
The mortality risk for lung cancer, cardiovascular illness, infection, and non-natural causes of death for transgender women was three and a half times more than that of cis women. Heart attacks were the biggest threat to transsexual women.
There was a 47.6-fold increase in death risk for HIV-infected women. And a 6.8-fold increase in mortality risk for transgender women. As with cis males, transgender men’s mortality risk was equal to that of cis women’s. But was almost double that of cis women. Transgender men’s mortality risk was 3.3 times that of cis women’s for the non-natural causes of death.
What are the reasons for high mortality risk in transgender?
Transgender women are more likely to die from cardiovascular disease. Also from HIV-related illness, suicide, and lung cancer than cis males and cis women. As a result of non-natural causes of death, the mortality risk for transgender males was higher than for cisgender women.
Such as suicide. It was shown that there was no difference in mortality risk between Tran males and cis guys. The gender-affirming hormone treatment and the majority of causes of mortality in transgender persons were not related to each other. It highlights the need for expanding societal acceptance. It also requires improving healthcare for transgender people.
Author Christen de Blok of Amsterdam University Medical Centre claimed that most HIV-related fatalities occurred in the first few decades. Improved HIV treatments and societal acceptability have decreased the number of transgender persons who have died as a result of these causes.
Patients with a history of cardiovascular disease were reluctant to receive hormone treatment. But today that is no longer the case because there are so many benefits to allowing people to receive hormone therapy.
There are two medical treatments that transgender persons use to achieve physical changes. Gender-affirming hormone therapy and surgery that more match their gender identification. Testosterone treatment promotes the development of masculine physical traits in transgender males. Ant androgens and Oestrogens are used to induce feminine physical characteristics in transgender males.
Dr. VIN Tangpricha said that extra evidence on the safety of gender-affirming hormone treatment in the transgender community should be published. He went on to say that transgender women experienced more comorbidities as a result of the therapy than transgender males.
What do the researchers find?
The chance of mortality in transgender persons was double that of cis males and cis women. Found in a nationwide study spanning five decades. The data show that the increased mortality risk for transgender persons did not diminish between 1972 and 2018.
Indicating that major health inequities must be addressed. Previous research has not determined if the pattern of higher mortality rates among transgender persons had altered throughout the decades.
Professor Martin den Heijer is the study’s principal author. She believes the data point to a long-term increase in mortality risk among transgender persons.
She added that improving societal acceptance and monitoring, treating cardiovascular illness, cigarette use, and HIV can reduce the death rate in transgender individuals. She also stated that further study on gender-affirming hormone treatment is needed to determine whether they are linked to transgender people’s mortality risk.
Share your thoughts in the comment section.